Scarica l'app Stockscreener
23.94
0.50%
-0.12
Dopo l'orario di chiusura:
24.29
0.35
+1.46%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Aktis Oncology Inc Borsa (AKTS) Ultime notizie
symbol__ Stock Quote Price and Forecast - CNN
AKTS Initiated Coverage by Oppenheimer -- Rating Set to Outperform - GuruFocus
Two New York investor events will include Aktis Oncology's CEO - Stock Titan
Oppenheimer initiates Aktis Oncology stock rating at Outperform - Investing.com
Oppenheimer initiates Aktis Oncology stock rating at Outperform By Investing.com - Investing.com Canada
Aktis Oncology (NASDAQ:AKTS) Trading Down 7.3%Should You Sell? - MarketBeat
Wellington Management Group LLP Takes $63.37 Million Position in Aktis Oncology $AKTS - MarketBeat
Aktis Oncology $AKTS Shares Purchased by BlackRock Inc. - MarketBeat
AKTS Q2 2026 Earnings: Clinical-Stage Biotech Reports Wider-Than-Expected Net LossQuarterly Profit Report - vinanet.vn
Jupiter Topco LLC Invests $42.36 Million in Aktis Oncology $AKTS - MarketBeat
Great Lakes Advisors LLC Takes $1.41 Million Position in Aktis Oncology $AKTS - MarketBeat
Blue Owl Capital Holdings LP Sells 91,129 Shares of Aktis Oncology $AKTS - MarketBeat
Aktis (AKTS) Earnings Snapshot: EPS Comes in Below Forecast in the Latest Session; Closing Reaction: The Share Price Sheds 4.08%Margin Guidance - vinanet.vn
AKTIS ONCOLOGY INC : WEDBUSH INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $35 - Bitget
Wedbush initiates Aktis Oncology stock with outperform rating By Investing.com - Investing.com South Africa
Aktis Oncology (NASDAQ:AKTS) Earns Outperform Rating from Analysts at Wedbush - MarketBeat
Why Novartis, Lilly, and Bristol Myers Are Eyeing This Clinical-Stage Cancer Play - Yahoo Finance
Wedbush Initiates Aktis Oncology at Outperform With $35 Price Target - marketscreener.com
BMO initiates Aktis Oncology stock with outperform rating By Investing.com - Investing.com Canada
AKTS Initiated Coverage by BMO Capital -- Rating Set to Outperfo - GuruFocus
Aktis Oncology (AKTS) Slips to $24.72 as Shares Trade Within Established RangeSynthetic Long - vinanet.vn
AKTS Q1 2026 Earnings: Wider-than-Expected Loss Reflects Ongoing Oncology Pipeline InvestmentLow Growth Earnings - vinanet.vn
Aktis Oncology, Inc.: Target Price Consensus and Analysts Recommendations | AKTS | US01021M1045 - marketscreener.com
BofA Securities Maintains Aktis Oncology(AKTS.US) With Buy Rating, Maintains Target Price $34 - Moomoo
AKTS SWOT Analysis: Financial Resilience Amidst Clinical Development Challenges Revealed in 10-Q Filing - GuruFocus
Aktis Oncology (NASDAQ:AKTS) Posts Earnings Results, Meets Expectations - marketbeat.com
Aktis Oncology Q2 EPS misses estimate, sales beat consensus - scanx.trade
Aktis: Q2 Earnings Snapshot - ktvb.com
Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026 - The Manila Times
Aktis Oncology (AKTS) builds cash to $517M as losses rise with clinical spend - Stock Titan
Aktis Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Aktis Oncology (AKTS) posts Q2 2026 results with $517M cash runway into 2029 - Stock Titan
Aktis Oncology (AKTS) Gains 2.94% as Shares Approach Key Resistance at $25.34Dividend ETF - dars.gov.et
Aktis Oncology (NASDAQ:AKTS) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Aktis Oncology (AKTS) Slips 1.5% as Shares Hover Above Key Support at $20.64Stop Run - vinanet.vn
AKTS Q1 2026 Earnings: Wider-than-Expected Loss of $0.38 Per Share Highlights Pre-Revenue ChallengesAnalyst Drop Coverage - vinanet.vn
AKTS Q1 2026 Earnings: Wider-than-Expected Loss of $0.38 Per Share, Yet Shares Climb 2.72%Revenue Warning Signal - vinanet.vn
Insider Selling: Aktis Oncology (NASDAQ:AKTS) Director Sells 4,856 Shares of Stock - MarketBeat
AKTS|Akoustis Technologies Ord Shs|Price:24.170|Chg%:+0.280 - TradingKey
Has Aktis Oncology (AKTS) Fallen Far Enough To Be Below Fair Value? - simplywall.st
AKTIS ONCOLOGY INC : LEERINK PARTNERS ASSUMES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $33 - Bitget
Aktis Oncology Inc : Leerink Partners Assumes - Moomoo
Aktis Oncology director Ken Herrmann sells $119,274 in stock By Investing.com - Investing.com Australia
Aktis Oncology (NASDAQ:AKTS) Stock Passes Above 50 Day Moving AverageHere's Why - MarketBeat
Form 4 Aktis Oncology Inc For: 21 July By Investing.com - Investing.com Nigeria
Aktis Oncology (AKTS) director sells 4,856 shares after exercising options - Stock Titan
Aktis Oncology director Ken Herrmann sells $119,274 in stock - Investing.com
Aktis Oncology director Ken Herrmann disposes of common shares worth $119,256.78 - Bitget
Aktis Oncology director Ken Herrmann disposes of 3,065 common shares worth $77,279.54 - Bitget
AKTS Pulls Back After Recent Gains: Key Levels to Watch for Aktis Oncology (AKTS)Volatility Skew - dars.gov.et
Aktis Oncology, Inc. (AKTS) director sells 3,065 post-exercise - Stock Titan
Akoustis Technologies (AKTS) insider plans 4,856-share stock sale after option exercise - Stock Titan
AKTS Options Chain — NASDAQ:AKTS - TradingView
Enterprise value to EBIT forward of Aktis Oncology, Inc. – NASDAQ:AKTS - TradingView
Enterprise value to revenue forward of Aktis Oncology, Inc. – NASDAQ:AKTS - TradingView
Form 144 AKTIS ONCOLOGY For: 17 July By Investing.com - Investing.com Nigeria
Aktis Oncology, Inc. SEC Filing (Jul 17, 2026) - Stock Titan
AKTS Options Volatility — NASDAQ:AKTS - TradingView
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):